SMARCA4 Antibody
| Code | Size | Price |
|---|
| PSI-7749-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7749-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Documents
Further Information
Additional Names:
SMARCA4 Antibody: BRG1, SNF2, SWI2, MRD16, RTPS2, BAF190, SNF2L4, SNF2LB, hSNF2b, BAF190A, BRG1, SNF2B, Transcription activator BRG1, ATP-dependent helicase SMARCA4
Application Note:
SMARCA4 antibody can be used for detection of SMARCA4 by Western blot at 1 - 2 μg/ml. Antibody can also be used for Immunohistochemistry at 2 μg/mL. For Immunoflorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse and rat samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse and rat samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
The SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily a member 4 (SMARCA4) protein, also known as BRG1, is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila (1). Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes (2). The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin (3). In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44 (4,5).
Background References:
- Muchardt C and Yaniv M. A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J. 1993; 12:4279-90.
- Wilson BG and Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011; 11:481-92.
- Bultman S, Gebuhr T, Yee D, et al. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol. Cell 2000; 6:1287-95.
- Bochar DA, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000; 102:257-65.
Buffer:
SMARCA4 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%)
Immunogen:
SMARCA4 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human SMARCA4.
The immunogen is located within amino acids 1420 - 1470 of SMARCA4.
The immunogen is located within amino acids 1420 - 1470 of SMARCA4.
NCBI Gene ID #:
6597
NCBI Official Name:
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
NCBI Official Symbol:
SMARCA4
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 185 kDa
Observed: 200 kDa
Observed: 200 kDa
Protein Accession #:
NP_001122321
Protein GI Number:
192807323
Purification:
SMARCA4 antibody is affinity chromatography purified via peptide column.
Research Area:
Homeostasis
SPECIFICITY:
SMARCA4 antibody is human, mouse and rat reactive. Multiple isoforms of SMARCA4 are known to exist.
Swissprot #:
P51532
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SMARCA4 Peptide | PSI-7749P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|